Premixed insulin: Advantages, disadvantages, and future

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Premixed insulin formulations combine rapid-acting and intermediate-acting insulins for simplified diabetes management in type 1 and type 2 diabetes.
• While convenient, fixed-ratio premixed insulins often result in inadequate glycemic control due to the inability to meet individual patient needs.
• Factors such as variable absorption kinetics and potential immune responses can further compromise the efficacy of conventional premixed insulins.

Discussion:

• The fixed ratios in traditional premixed insulins do not accommodate the dynamic and individualized requirements for glucose-lowering therapy.
• Local absorption issues and systemic autoimmune reactions associated with co-formulated insulins can negatively impact overall glycemic control.
• The development of novel insulin combinations seeks to overcome these inherent limitations of existing premixed insulin products.

Key Insights:

• Co-formulation of insulin degludec and insulin aspart represents a novel approach to premixed insulin therapy.
• This new combination aims to provide a more flexible and effective solution for patients requiring basal-bolus insulin regimens.
• Addressing the shortcomings of conventional premixed insulins, this formulation may offer improved blood glucose management.

Outlook:

• Further clinical evaluation is necessary to establish the long-term safety and efficacy of insulin degludec/insulin aspart co-formulation.
• This innovative premixed insulin holds potential for enhancing patient convenience and achieving better glycemic control in diabetes management.
• Future research may focus on optimizing dosing strategies and patient selection for this advanced insulin combination therapy.